<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2678023-A1" country="EP" doc-number="2678023" kind="A1" date="20140101" family-id="45787177" file-reference-id="265697" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146551448" ucid="EP-2678023-A1"><document-id><country>EP</country><doc-number>2678023</doc-number><kind>A1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12706804-A" is-representative="NO"><document-id mxw-id="PAPP154825371" load-source="docdb" format="epo"><country>EP</country><doc-number>12706804</doc-number><kind>A</kind><date>20120222</date><lang>EN</lang></document-id><document-id mxw-id="PAPP204142019" load-source="docdb" format="original"><country>EP</country><doc-number>12706804.7</doc-number><date>20120222</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140445385" ucid="EP-2012052992-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2012052992</doc-number><kind>W</kind><date>20120222</date></document-id></priority-claim><priority-claim mxw-id="PPC140452027" ucid="US-201161445601-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161445601</doc-number><kind>P</kind><date>20110223</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988099778" load-source="docdb">A61K  36/752       20060101ALI20120913BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988106576" load-source="docdb">A61P  17/14        20060101ALI20120913BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988114690" load-source="docdb">A61K  36/8962      20060101ALI20120913BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988116650" load-source="docdb">A61K  36/185       20060101AFI20120913BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988127529" load-source="docdb">A61K  36/77        20060101ALI20120913BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988098899" load-source="docdb" scheme="CPC">A61K  36/77        20130101 LI20131206BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988109302" load-source="docdb" scheme="CPC">A61K  36/185       20130101 FI20131206BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988115112" load-source="docdb" scheme="CPC">A61K  36/752       20130101 LI20131206BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988118526" load-source="docdb" scheme="CPC">A61K  36/8962      20130101 LI20131206BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988130028" load-source="docdb" scheme="CPC">A61K  36/88        20130101 LI20131127BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132186828" lang="DE" load-source="patent-office">NEUE VERWENDUNG VON ZUSAMMENSETZUNGEN ZUR VORBEUGUNG VON CHEMOTHERAPIE- UND RADIOTHERAPIEINDUZIERTER ALOPEZIE (CRIA), VERRINGERUNG DER AUSWIRKUNGENVON CRIA UND VERBESSERUNG DES ERSCHEINUNGSBILDES DES HAARNACHWUCHSES NACH CRIA</invention-title><invention-title mxw-id="PT132186829" lang="EN" load-source="patent-office">NEW USE OF COMPOSITIONS FOR PREVENTING CHEMOTHERAPY AND RADIOTHERAPY INDUCED ALOPECIA (CRIA), REDUCING CRIA IMPACT AND IMPROVING THE APPEARANCE OF HAIR RE-GROWTH AFTER CRIA</invention-title><invention-title mxw-id="PT132186830" lang="FR" load-source="patent-office">NOUVELLE UTILISATION DE COMPOSITIONS POUR PRÉVENIR L'ALOPÉCIE INDUITE PAR CHIMIOTHÉRAPIE ET RADIOTHÉRAPIE (CRIA), RÉDUIRE L'IMPACT DE LA CRIA ET AMÉLIORER L'ASPECT DE LA REPOUSSE DES CHEVEUX APRÈS CRIA</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918132481" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>LEGACY HEALTHCARE LTD</last-name><address><country>MT</country></address></addressbook></applicant><applicant mxw-id="PPAR918149898" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LEGACY HEALTHCARE LTD</last-name></addressbook></applicant><applicant mxw-id="PPAR918982157" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Legacy Healthcare Ltd</last-name><iid>101400754</iid><address><street>85 St John Street Valleta</street><city>Malta, VLT 1165</city><country>MT</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918140919" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HARTI SAAD</last-name><address><country>CH</country></address></addressbook></inventor><inventor mxw-id="PPAR918157153" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HARTI, SAAD</last-name></addressbook></inventor><inventor mxw-id="PPAR918982318" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>HARTI, SAAD</last-name><address><street>Place de la Gare 22</street><city>CH-1095 Lutry</city><country>CH</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918989257" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Hirsch &amp; Associés</last-name><iid>100061101</iid><address><street>58, avenue Marceau</street><city>75008 Paris</city><country>FR</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2012052992-W"><document-id><country>EP</country><doc-number>2012052992</doc-number><kind>W</kind><date>20120222</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012113820-A1"><document-id><country>WO</country><doc-number>2012113820</doc-number><kind>A1</kind><date>20120830</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548867159" load-source="docdb">AL</country><country mxw-id="DS548918461" load-source="docdb">AT</country><country mxw-id="DS548867160" load-source="docdb">BE</country><country mxw-id="DS548838319" load-source="docdb">BG</country><country mxw-id="DS548934273" load-source="docdb">CH</country><country mxw-id="DS548816924" load-source="docdb">CY</country><country mxw-id="DS548816925" load-source="docdb">CZ</country><country mxw-id="DS548939822" load-source="docdb">DE</country><country mxw-id="DS548867161" load-source="docdb">DK</country><country mxw-id="DS548867162" load-source="docdb">EE</country><country mxw-id="DS548936110" load-source="docdb">ES</country><country mxw-id="DS548838320" load-source="docdb">FI</country><country mxw-id="DS548838321" load-source="docdb">FR</country><country mxw-id="DS548939823" load-source="docdb">GB</country><country mxw-id="DS548867163" load-source="docdb">GR</country><country mxw-id="DS548939824" load-source="docdb">HR</country><country mxw-id="DS548816926" load-source="docdb">HU</country><country mxw-id="DS548934278" load-source="docdb">IE</country><country mxw-id="DS548867164" load-source="docdb">IS</country><country mxw-id="DS548838322" load-source="docdb">IT</country><country mxw-id="DS548867165" load-source="docdb">LI</country><country mxw-id="DS548939825" load-source="docdb">LT</country><country mxw-id="DS548918466" load-source="docdb">LU</country><country mxw-id="DS548838323" load-source="docdb">LV</country><country mxw-id="DS548939830" load-source="docdb">MC</country><country mxw-id="DS548918467" load-source="docdb">MK</country><country mxw-id="DS548918468" load-source="docdb">MT</country><country mxw-id="DS548838324" load-source="docdb">NL</country><country mxw-id="DS548934279" load-source="docdb">NO</country><country mxw-id="DS548838325" load-source="docdb">PL</country><country mxw-id="DS548936111" load-source="docdb">PT</country><country mxw-id="DS548939831" load-source="docdb">RO</country><country mxw-id="DS548936112" load-source="docdb">RS</country><country mxw-id="DS548838326" load-source="docdb">SE</country><country mxw-id="DS548929697" load-source="docdb">SI</country><country mxw-id="DS548934280" load-source="docdb">SK</country><country mxw-id="DS548934281" load-source="docdb">SM</country><country mxw-id="DS548867166" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99625596" ref-ucid="WO-2012113820-A1" lang="EN" load-source="patent-office"><p num="0000">A new use of compositions administered by topical route containing as active ingredient an extract of <i>Allium species</i>, an extract of <i>Citrus species</i>, an extract of <i>Paullinia</i> species and an extract of <i>Theobroma species</i>, for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. A method for preventing, reducing impact and improving the appearance of hair re-growth on a human (do you want to claim veterinary use as well?) head before, during and after CRIA, said method comprising the administration by topical route of a composition containing as active ingredient an extract of <i>Allium species</i>, an extract of <i>Citrus species</i>, an extract of <i>Paullinia</i> species and an extract of <i>Theobroma species</i>.</p></abstract><abstract mxw-id="PA99824115" ref-ucid="WO-2012113820-A1" lang="EN" source="national office" load-source="docdb"><p>A new use of compositions administered by topical route containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. A method for preventing, reducing impact and improving the appearance of hair re-growth on a human (do you want to claim veterinary use as well?) head before, during and after CRIA, said method comprising the administration by topical route of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species.</p></abstract><abstract mxw-id="PA99625597" ref-ucid="WO-2012113820-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne une nouvelle utilisation de compositions administrées par voie topique contenant en tant que substance active un extrait d'espèces <i>Allium</i>, un extrait d'espèces <i>Citrus</i>, un extrait d'espèces <i>Paullinia</i> et un extrait d'espèces <i>Theobroma</i>, pour prévenir la CRIA, réduire l'impact de la CRIA et améliorer l'aspect de la repousse des cheveux après CRIA. La présente invention concerne un procédé pour prévenir, réduire l'impact et améliorer l'aspect de la repousse des cheveux sur la tête d'un humain (souhaitez-vous revendiquer l'utilisation vétérinaire également ?) avant, pendant et après CRIA, ledit procédé comprenant l'administration par voie topique d'une composition contenant en tant que substance active un extrait d'espèces <i>Allium</i>, un extrait d'espèces <i>Citrus</i>, un extrait d'espèces <i>Paullinia</i> et un extrait d'espèces <i>Theobroma</i>.</p></abstract><abstract mxw-id="PA99824116" ref-ucid="WO-2012113820-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne une nouvelle utilisation de compositions administrées par voie topique contenant en tant que substance active un extrait d'espèces Allium, un extrait d'espèces Citrus, un extrait d'espèces Paullinia et un extrait d'espèces Theobroma, pour prévenir la CRIA, réduire l'impact de la CRIA et améliorer l'aspect de la repousse des cheveux après CRIA. La présente invention concerne un procédé pour prévenir, réduire l'impact et améliorer l'aspect de la repousse des cheveux sur la tête d'un humain (souhaitez-vous revendiquer l'utilisation vétérinaire également ?) avant, pendant et après CRIA, ledit procédé comprenant l'administration par voie topique d'une composition contenant en tant que substance active un extrait d'espèces Allium, un extrait d'espèces Citrus, un extrait d'espèces Paullinia et un extrait d'espèces Theobroma.</p></abstract><description mxw-id="PDES50931314" ref-ucid="WO-2012113820-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> NEW USE OF COMPOSITIONS FOR PREVENTING CHEMOTHERAPY AND RADIOTHERAPY INDUCED ALOPECIA (CRIA), REDUCING CRIA IMPACT AND IMPROVING THE APPEARANCE OF HAIR RE-GROWTH AFTER CRIA </p><p id="p0002" num="0002">BACKGROUND AND SUMMARY </p><p id="p0003" num="0003"> The invention concerns a new use of compositions containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, preventing CRIA (Chemotherapy and Radiotherapy Induced Alopecia), reducing CRIA impact and improving the appearance of hair re-growth after CRIA , and methods thereof. </p><p id="p0004" num="0004"> From patent application WO 2008/1 13912 it is known that, compositions containing as active ingredient an extract of Allium species, an extract of Citrus species and </p><p id="p0005" num="0005"> - either an extract of Paullinia species and an extract of Theobroma species </p><p id="p0006" num="0006"> - or an extract of Salix species and zinc sulphate increase the hair growth.. </p><p id="p0007" num="0007">At the cellular level, CRIA (Chemotherapy and Radiotherapy Induced Alopecia) originates from the premature on-set of the catagen phase of the hair due to the destruction (apoptosis) by a chemotherapy agent of the cells in the hair follicles, especially the cells linking the hair to the dermal papilla. </p><p id="p0008" num="0008">The catagen phase consists in the involution of the hair follicle and beginning of detachment of the hair from the dermal papilla, due to the entry into massive apoptosis 
<!-- EPO <DP n="3"/>-->
 (programmed cell death) of the cells in the hair follicles, in particular the cells linking the hair to the dermal papilla. </p><p id="p0009" num="0009">At the molecular level, previous studies using a mouse chemotherapy induced alopecia model have shown that p53, a pro-apoptotic and tumor suppressor protein, played essential roles in mediating anticancer agent-induced apoptosis in hair follicles. </p><p id="p0010" num="0010">Such an apoptosis-promoting effect may involve numerous p53 responsive genes acting through different mechanisms. For instance, p53 up-regulates transcription of Bax and down-regulates transcription of Bcl-2, thus decreasing the Bcl-2/Bax ratio and predisposing cells to apoptosis. It has also been suggested that p53 is involved in mediating DNA damage responses in the hair follicles induced by chemotherapeutic agents, hence in the control of hair regression. </p><p id="p0011" num="0011">Interestingly, pharmacological or genetic suppression of p53 in mice greatly reduced or prevented chemotherapy-induced apoptosis in hair matrix keratinocytes and hair loss. </p><p id="p0012" num="0012">The above-mentioned investigational work indicates that inhibition of pro- apoptotic protein or re-establishment of the balance of intracellular levels of pro- and anti- apoptotic proteins (such as p53 and Bcl-2) in hair follicles may serve as an effective treatment for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. </p><p id="p0013" num="0013">It has been shown that application of compositions containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, enables the increase of the intracellular BCL2 (an 
<!-- EPO <DP n="4"/>-->
 anti-apoptotic protein) to its normal level, hence enabling the cells in the hair follicles, specially the cells linking the hair to the dermal papilla not to enter into premature apoptosis, as provoked by the chemotherapy agent. </p><p id="p0014" num="0014">The delay of the premature on-set of the catagen phase enables the hair remain in its anagen phase longer, and therefore not fall because of the action of the chemotherapy agent. </p><p id="p0015" num="0015">Advances in cancer treatment have enabled patients to live longer, more productive lives and to continue working and enjoying normal social and recreational activities. The most visible and emotionally distressing side effect of cancer therapy is Chemotherapy and Radiotherapy Induced Alopecia (CRIA). Partial or total hair loss is a constant source of stress for the patient and a public display of underlying disease. Clinical studies of women undergoing cancer treatment consistently identify alopecia as the most traumatic side effect of chemotherapy, associated with low self-esteem, poor body image, and diminished quality of life. Men are also profoundly affected by CRIA , but there are few support groups or educational/assistive services available to help male chemotherapy and radiotherapy patients cope with the psychologically damaging effects of hair loss. </p><p id="p0016" num="0016"> CRIA occurs when rapidly growing and dividing cell populations in anagen phase follicles are damaged by the systemic chemotoxic agents or radiotherapy killing actively growing tumor cells. CRIA is a temporary condition; hair growth for the majority of patients resumes when damaged follicles remodel and re-enter anagen phase. However, restoration of the normal anagen to telogen ratio of 9:1 can take from six months to one year. From the perspective of hair cycle biology, an effective treatment 
<!-- EPO <DP n="5"/>-->
 for CRIA would protect susceptible, rapidly growing bulb matrix cells from the destructive effects of systemic chemotherapy agent(s). Alternatively, CRIA patients could benefit from a product that would rapidly induce normal hair growth by accelerating the synchronized transition of damaged follicles from telogen to anagen phase to restore the normal anagen to telogen ratio and cosmetically normal hair. </p><p id="p0017" num="0017"> It has been discovered that the administration by topical route of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species has a novel and unexpected effect preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. Thus the present invention concerns a new use of compositions administered by topical route, containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. </p><p id="p0018" num="0018"> DETAILED DESCRIPTION </p><p id="p0019" num="0019"> A first observation has been made during a study with depilated mice. The study was conducted as a model of chemotherapyinduced anagen effluvium to evaluate the efficacy of a topical active ingredient containing an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, to accelerate the rate of hair re-growth. In addition, one case report of a female patient undergoing chemotherapy seems to support animal observations. </p><p id="p0020" num="0020"> Another object of the invention is also a new use of topical compositions containing an aqueous-alcoholic extract of Allium species, an aqueous-alcoholic extract of Citrus species, an aqueous alcoholic extract (atomised or not) of Paullinia species 
<!-- EPO <DP n="6"/>-->
 and an aqueous-alcoholic extract (atomised or not) of Theobroma species, for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. Most preferably, the compositions are used before, during and after CRIA. </p><p id="p0021" num="0021">Among the new use for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA., according to the invention, those which are of more particular interest are those in which the preferred topical composition contains from 65% to 93% of an aqueous-alcoholic extract of Allium species, from 5% to 33% of an aqueous-alcoholic extract of Citrus species, from 0.25% to 2.5% of an aqueous alcoholic extract (atomised or not) of Paullinia species and from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Theobroma species. Among the methods for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA., according to the invention, those which are the more preferred interest are the methods in which the compositions are containing from 65% to 93% of an aqueous-alcoholic extract of Allium species, from 5% to 33% of an aqueous- alcoholic extract of Citrus species, from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Paullinia species and from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Theobroma species and especially those containing from 65% to 93% of an aqueous-alcoholic extract of Allium cepa, from 5% to 33% of an aqueous-alcoholic extract of Citrus lemon, from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Paullinia species and from 0.25% to 2.5% of an aqueous- alcoholic extract (atomised or not) of Theobroma species. </p><p id="p0022" num="0022"> The term extract of Allium species or aqueous-alcoholic extract of Allium species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all 
<!-- EPO <DP n="7"/>-->
 species of the genus Allium (family Liliaceae) and especially Allium cepa. The term extract of Citrus species or aqueous-alcoholic extract of Citrus species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Citrus (family Rutaceae) and especially Citrus lemon. The term extract (atomised or not) of Paullinia species or aqueous-alcoholic extract (atomised or not) of Paullinia species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Paullinia (family Sapindaceae) and especially Paullinia cupana. The term extract (atomised or not) of Theobroma species or aqueous-alcoholic extract (atomised or not) of Theobroma species refers particularly to aqueous-alcoholic extracts and native extracts obtained from all species of the genus Theobroma (family Malvaceae) and especially Theobroma cacao. </p><p id="p0023" num="0023"> The most preferred compositions used according to the invention are those containing approximately 87% of an aqueous-alcoholic extract of Allium cepa, approximately 12% of an aqueous-alcoholic extract of Citrus lemon, approximately 0.5% of an aqueous-alcoholic extract (atomised or not) of Paullinia cupana and approximately 0.5% of an aqueous-alcoholic extract (atomised or not) of Theobroma cacao; </p><p id="p0024" num="0024"> These compositions are prepared as indicated in patent application WO 2008/1 13912, which is incorporated by reference herein. These cosmetical or pharmaceutical compositions are prepared by conventional methods, in which inert, organic or inorganic excipients are added to the compositions obtained according to the invention. </p><p id="p0025" num="0025"> According to the invention the composition is administered daily, before the chemotherapy or radiotherapy, during the chemotherapy or radiotherapy , and up to six months after chemotherapy or radiotherapy has ended, with a composition containing as 
<!-- EPO <DP n="8"/>-->
 active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species. </p><p id="p0026" num="0026"> In order to obtain a cosmetically satisfying effect on the hair growth, it is necessary to perform the administration of the compositions during up to 6 months after the chemotherapy or radiotherapy treatment has ended. When using the compositions obtained according to the invention, doses may vary within relatively wide limits and must be set according to the person being treated and the condition concerned. Pharmaceutical compositions normally contain from 0.2 to 500 mg, preferably from 1 to 200 mg, of active ingredients as defined above, in the form of dry extract. </p><p id="p0027" num="0027"> Based on previous observations, we hypothesized that the compositions according to the invention might effectively suit CRIA patients, whose follicles are prematurely forced into telogen phase by many chemotherapy agents, causing widespread hair loss. A mouse depilation model was used to simulate chemotherapy- induced anagen effluvium to determine whether this topical biotherapy could accelerate the rate of hair growth in a chemotherapy induced alopecia model and / or protect hair follicles in chemotherapy-affected scalp from undergoing abnormal apoptosis-driven regression (catagen followed by telogen phase). This will provide support for clinical evaluation of the topical extract as an easy-to-use, natural solution for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. </p><p id="p0028" num="0028">Examples of Compositions </p><p id="p0029" num="0029"> As a drug </p><p id="p0030" num="0030">Hair Lotion </p><p id="p0031" num="0031"> Active ingredient: Composition A ..................... 40 g per 100 ml 
<!-- EPO <DP n="9"/>-->
 Excipients: aqueous ethanol at 55 ° </p><p id="p0032" num="0032">Treatment : Application 1 -2 times daily friction </p><p id="p0033" num="0033">A cosmetics </p><p id="p0034" num="0034">1 °) Hair Lotion </p><p id="p0035" num="0035"> Active ingredient: Composition A...... ..........21 g per 100 ml </p><p id="p0036" num="0036"> Ingredients: aqua, alcohol, betaine, glycerin, polysorbate 20, maltodextrin, silica. </p><p id="p0037" num="0037">Treatment : Application 1 to 2 times daily friction. </p><p id="p0038" num="0038">2°) Hair Gel </p><p id="p0039" num="0039"> Active ingredient: Composition A.............. .......21 % </p><p id="p0040" num="0040"> Excipients: 96% ethanol (10%), betaine 2%, 5% glycerol, Ultragel 300 (1 %), Sterile demineralized water qs 100%. </p><p id="p0041" num="0041"> Treatment : Application 1 to 2 times daily massage. </p><p id="p0042" num="0042"> 3°) Shampoo </p><p id="p0043" num="0043"> Active ingredient: Composition A ...........................10 % </p><p id="p0044" num="0044"> Excipients: sodium dodecyl sulfate at 25% (10%), sodium chloride, 3% citric acid 0.1 %, 0.5% imidazolydinyluree, demineralized water sterile qs 100% </p><p id="p0045" num="0045">Treatment : 1 shampoo every day. </p><p id="p0046" num="0046">4°) After Shampoo </p><p id="p0047" num="0047"> Active ingredient: Composition A .20 % </p><p id="p0048" num="0048"> Excipients: Montanov 68 (5%), DM Amonyl 2%, 3% dimethicone, imidazolydinyluree 0.5%, sterile demineralized water qs 100%. </p><p id="p0049" num="0049">Treatment : 1 shampoo every day. 
<!-- EPO <DP n="10"/>-->
 Experiment on mice </p><p id="p0050" num="0050"> Materials and Methods </p><p id="p0051" num="0051">Test Substance </p><p id="p0052" num="0052"> A topical solution, according to the present invention, containing, Allium cepa extract (50%), Citrus medica Limonum (15%) extract, Paullinia cupana (0.50 %) and Theobroma cacao (0.50 %) was used (hereafter composition B). </p><p id="p0053" num="0053">Hair cycle induction </p><p id="p0054" num="0054"> Synchronized development of the telogen phase on the back skin of 7-week-old male BALB/C mice was induced by depilation as described by Paus et al.( Paus R, Stenn KS, Link RE. Telogen skin contains an inhibitor of hair growth. Br J Dermatol. 1990; 22:777- 784) Thirty mice (15 control/15 treated) were evaluated for 21 days. The experimental group was treated twice daily with 1 ml of the test substance applied by spray </p><p id="p0055" num="0055">application to the depilated area. Food and water were provided ad libitum. </p><p id="p0056" num="0056">Skin Samples </p><p id="p0057" num="0057"> Back skin was harvested from control and treated mice at 2, 4, 7, 14 and 21 days after depilation (three mice per time point). Longitudinal and transverse skin sections were fixed with phosphate-buffered formalin (pH 7.2) at room temperature for 24 h and then embedded in paraffin wax. Paraffin sections were stained with a haematoxylin-eosin solution for routine histopathological examination and hair follicle counts, and with Sirius Red for collagen. </p><p id="p0058" num="0058">Hair Follicle Counts </p><p id="p0059" num="0059"> Transverse skin sections were assessed for hair follicle counts according to their growth phase. Hair in the anagen phase was detected by the presence of the inner root sheath. Telogen follicles were identified by a striking thickening of the basement membrane 
<!-- EPO <DP n="11"/>-->
 zone and vellus for inner root &lt; 0.03 mm <sup>6</sup>. Hair follicles were counted using a light microscope at 200X magnification. Maximum and minimum hair follicle and inner root diameters were measured and expressed in micrometers (μιη). </p><p id="p0060" num="0060">Histomorphometric Evaluation </p><p id="p0061" num="0061"> Microscopic analysis was performed using the Image Analysis System and images were processed using Kontron 300 software (Zeiss). Fifteen to 20 different fields were randomly selected inside a square reticulum (60,000 μιη<sup>2</sup>) for hair follicle counts. The area of the dermis was determined by image analysis at 200X magnification. </p><p id="p0062" num="0062">Collagen threshold level was established for each slide in a dermis area (60,000 μιη<sup>2</sup>) after enhancing the contrast to the point at which the collagen fibers were easily identified. The area occupied by the collagen fibers was determined by digital densitometric recognition by adjusting the threshold level of measurement up to the grey density. The relative area of collagen was expressed as the percentage of collagen in the dermis area. </p><p id="p0063" num="0063">Statistical Methods </p><p id="p0064" num="0064"> Statistical analyses were performed using either the Student's t-test when evaluating between-group differences and simple regression analysis to evaluate the correlation between hair follicle counts and days of treatment. Data were computed using </p><p id="p0065" num="0065">SigmaStat software (Jandel Corp, </p><p id="p0066" num="0066"> CA, United States). Significant data were considered to be p&lt;0.05. </p><p id="p0067" num="0067">Data Quality Assurance </p><p id="p0068" num="0068"> The study was carried out according to the Good Laboratory Practices as defined by</p><p id="p0069" num="0069">INMETRO regulation. </p><p id="p0070" num="0070"> Results 
<!-- EPO <DP n="12"/>-->
 Hair Growth Analysis </p><p id="p0071" num="0071"> The numbers of anagen phase hairs increased for seven days after depilation in treated and control animals, and at all times after depilation up to the end of the 21 -day observation period, when the number of anagen follicles in the treatment group was significantly greater than in controls (p&lt;0.001 , Figure 1 ). There were significantly fewer telogen follicles in treated animals than in controls at all time points evaluated (p&lt;0.001 ) up to the end of the 21 -day observation period (Figure 2). The A:T after 21 days of treatment was approximately 9:1 compared to approximately 3:1 in controls. </p><p id="p0072" num="0072">Collagen Deposition </p><p id="p0073" num="0073"> An increase in collagen deposition in the dermis of treated mice in the test group was observed, with a significant positive linear correlation between the percentage of collagen deposited and the days of treatment (p&lt;0.001 , Figure 3). In the control group, there was no significant correlation of collagen deposition after depilation (p&gt;0.05). When the amounts of collagen in the dermis of mice from the test group and the control group were compared, there was a significantly greater amount of collagen deposition in the dermis of mice in the test group (p&lt;0.001 , Figure 4). </p><p id="p0074" num="0074"> Clinical Experiment </p><p id="p0075" num="0075"> During a period of 4 months, the patients have received, every day on the scalp a lotion containing: </p><p id="p0076" num="0076"> - an aqueous-alcoholic extract of Allium cepa: 87.04 % </p><p id="p0077" num="0077"> - an aqueous-alcoholic extract of Citrus lemon: 1 1 .96 % </p><p id="p0078" num="0078"> - an atomised aqueous-alcoholic extract of Paullinia cupana: 0.50 % </p><p id="p0079" num="0079"> - an atomised aqueous-alcoholic extract of Theobroma cacao: 0.50 % </p><p id="p0080" num="0080">(hereafter composition A). 
<!-- EPO <DP n="13"/>-->
 This lotion has been prepared as indicated in example 1 of patent application WO 2008/1 13912. </p><p id="p0081" num="0081"> Composition A which is a mixture of four natural ingredients has been reported to beneficially affect the Anagen/Telogen ratio in men with androgenetic alopecia and women suffering from Female Pattern Hair Loss. In addition, people using the product occasionally accelerated re-growth of hair. This has suggested that composition A is capable of affecting positively the hair cycle after the shedding (exogen) process, in order to provoke a quicker restart of next hair growth (anagen) phase, as such shortening the resting phase. Because of the observation hereafter, one patient with cancer who underwent chemotherapy, and consequently suffered from chemotherapy induced alopecia, has used the composition of the invention to evaluate its efficacy on starting hair re-growth after chemotherapy. These observations are summarized hereafter. </p><p id="p0082" num="0082"> Observations </p><p id="p0083" num="0083"> Patient BH (Born on Dec 1938), female, was diagnosed with uterine cancer in July 2003. She went into a first surgery in September 2003 and a second surgery on October 2003. She underwent five courses of a first chemotherapy (Carbo+Taxol), starting November 2003, and then four courses of a second chemotherapy (Carbo), over a total period of seven months and gradually ended-up with total hair loss after the second course of chemotherapy. </p><p id="p0084" num="0084"> A few weeks after the last course of chemotherapy, her hair started growing back, in an uneven, patchy pattern. She started using the composition A of the invention a few weeks after her hair started growing back. She applied the product twice a day (morning and evening) for several months. 
<!-- EPO <DP n="14"/>-->
 Within a few weeks after starting the composition A application, the patient and her environment noticed an accelerated and even outgrowth of hairs, eliminating the patchy re-growth pattern completely. Three months after starting the application of composition A, the coverage of the scalp by the hair came back to what it was prior to chemotherapy. </p><p id="p0085" num="0085"> The patient reported that a few weeks after starting with composition A she did not require a wig anymore. The patient was extremely satisfied with the results and requested to continue using the composition on an on-going basis. Currently she has been using the composition A for 6 years without side effects and remains satisfied with the condition of the scalp. </p><p id="p0086" num="0086"> Conclusion </p><p id="p0087" num="0087"> Although this observation relates to an extremely small number (n=1 ), supported by the study on mice, the findings are remarkably similar and support the hypothesis that the product is capable of accelerating the re-growth of hair after exogen and as such shortening the resting phase. Consequently, this warrants further investigation in larger numbers of cancer patients to evaluate to what extend the product can prevent hair loss, slow-down hair loss, or accelerate hair re-growth after CRIA. In addition, it appears that the re-growth pattern observed may result in a more rapid overall cosmetic recovery of the cancer patient after treatment. 
</p></description><claims mxw-id="PCLM44727268" ref-ucid="WO-2012113820-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="15"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>1 . A new use of compositions administered by topical route, containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and an extract of Theobroma species, for preventing CRIA, reducing CRIA impact and improving the appearance of hair re-growth after CRIA. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. A new use of topical compositions containing an aqueous-alcoholic extract of Allium species, an aqueous-alcoholic extract of Citrus species, an aqueous alcoholic extract (atomised or not) of Paullinia species and an aqueous-alcoholic extract (atomised or not) of Theobroma species, for preventing, reducing impact and improving the appearance of hair re-growth according to Claim 1 , for patients before, during and after CRIA. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. A new use of topical compositions containing from 65% to 93% of an aqueous-alcoholic extract of Allium species, from 5% to 33% of an aqueous-alcoholic extract of Citrus species, from 0.25% to 2.5% of an aqueous alcoholic extract (atomised or not) of Paullinia species and from 0.25% to 2.5% of an aqueous-alcoholic extract (atomised or not) of Theobroma species, for for preventing, reducing impact and improving the appearance of hair re-growth according to Claims 1 and 2, for patients before, during and after CRIA. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. A new use of topical compositions containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of Paullinia species and <!-- EPO <DP n="16"/>--> an extract of Theobroma species, for preventing, reducing impact and improving the appearance of hair re-growth according to Claims 1 to 3 for patients before, during and after CRIA, wherein the composition is administered daily during a period of several months. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. A new use of topical compositions according to claims 1 to 4, wherein the compositions contain from 0.2 to 500 mg in the form of dry extract. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. A new use of topical compositions according to claims 5, wherein the compositions contain from 1 to 200 mg in the form of dry extract. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. A method for preventing, reducing impact and improving the appearance of hair re-growth on a human head/scalp before, during and after CRIA, the method comprising the administration by topical route of a composition containing as active ingredient an extract of Allium species, an extract of Citrus species, an extract of </claim-text><claim-text>Paullinia species and an extract of Theobroma species. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
